Abstract
In a recent landmark trial of bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) isolates, vancomycin MICs were >or=1 microg/ml for only 16% of the isolates, and accessory gene regulator (agr) function as measured by delta-hemolysin activity was absent or reduced in only 28.1% of the isolates. This clinical study did not capture a population of MRSA isolates predictive of vancomycin treatment failure.
Publication types
-
Clinical Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Bacteremia / drug therapy
-
Bacteremia / microbiology*
-
Bacterial Proteins / genetics
-
Bacterial Proteins / metabolism
-
Daptomycin / pharmacology
-
Daptomycin / therapeutic use
-
Endocarditis, Bacterial / drug therapy
-
Endocarditis, Bacterial / microbiology
-
Genotype
-
Hemolysin Proteins / genetics
-
Hemolysin Proteins / metabolism
-
Humans
-
Methicillin Resistance*
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / microbiology*
-
Staphylococcus aureus / classification*
-
Staphylococcus aureus / drug effects
-
Staphylococcus aureus / genetics*
-
Treatment Outcome
-
Vancomycin / pharmacology
-
Vancomycin / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Hemolysin Proteins
-
Vancomycin
-
delta hemolysin protein, Staphylococcus aureus
-
Daptomycin